<DOC>
	<DOCNO>NCT00000767</DOCNO>
	<brief_summary>To evaluate , healthy HIV-1 seronegative vaccinia-immune vaccinia-naive volunteer , safety immunogenicity HIV-1 candidate vaccine ( TBC-3B ) consist live recombinant vaccinia virus express env , gag , pol gene HIV-1 IIIB strain . To evaluate potential boost one variety HIV-1 recombinant subunit , peptide , pseudovirion vaccine , available , augment immune response vaccinee . Antigenic drift , define genetic variation HIV-1 envelope gene result antigenic variation natural infection , may confound attempt achieve protective immunity use vaccine base solely HIV-1 envelope protein . Inclusion conserve core polymerase protein along envelope protein candidate vaccine may address problem antigenic variability . A prime-boost immunization approach use novel prim immunogen express env , gag , pol gene HIV-1 IIIB strain attempt study .</brief_summary>
	<brief_title>A Multicenter , Randomized , Placebo-Controlled , Double-Blind Trial Evaluate Safety Immunogenicity Recombinant Vaccinia-HIV-1 IIIB Env/Gag/Pol Vaccine ( TBC-3B )</brief_title>
	<detailed_description>Antigenic drift , define genetic variation HIV-1 envelope gene result antigenic variation natural infection , may confound attempt achieve protective immunity use vaccine base solely HIV-1 envelope protein . Inclusion conserve core polymerase protein along envelope protein candidate vaccine may address problem antigenic variability . A prime-boost immunization approach use novel prim immunogen express env , gag , pol gene HIV-1 IIIB strain attempt study . In Part I , vaccinia-immune volunteer randomize one two regimen . Group A receive prim TBC-3B day 0 56 , follow boosting day 224 ( 8 month ) one follow : TBC-3B , alternative immunogen pseudovirion particle recombinant HIV-1 subunit peptide vaccine , placebo . Group B receive prim control vaccine ( DryVax ) , follow boost appropriate placebo . At least 50 percent subject Part I observe minimum 8 week subsequent volunteer enrol Part II . PER 11/18/94 AMENDMENT , Part I boost give day 392 . PER 5/19/95 AMENDMENT , Part I boost give day 756 available day 392 ; appropriate product available , study end day 756 . In Part II , vaccinia-naive volunteer randomize one three regimen . Group C receive TBC-3B day 0 saline placebo day 56 . Group D receive TBC-3B day 0 56 . Both Group C D receive boost TBC-3B alternative immunogen day 224 . Group E receive control vaccine ( DryVax ) day 0 56 , follow appropriate placebo day 224 . Per 06/10/94 addendum , volunteer contact twice per year least 5 year check health status . NOTE : Part I ( Part A ) protocol close accrual .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccinia</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria Subjects must : Negative ELISA Western blot HIV1 within 6 week prior immunization . Normal history physical exam . History smallpox vaccination least 5 year prior study entry ( Part I ) OR prior smallpox vaccination ( Part II ) . Absolute CD4 count &gt; = 400 cells/mm3 . Normal urinalysis . NOTE : No 10 percent volunteer Parts I II may 50 year age . Exclusion Criteria Coexisting Condition : Subjects follow symptoms condition exclude : Positive hepatitis B surface antigen . Medical psychiatric condition ( recent suicidal ideation present psychosis ) preclude compliance . Occupational responsibility preclude compliance . Active syphilis . NOTE : Subjects serology document false positive due remote ( &gt; 6 month ) treat infection eligible . Active tuberculosis . NOTE : Subjects positive PPD normal chest xray show evidence TB require isoniazid therapy eligible . Eczema . Household contact person meet follow criterion : pregnancy , less 12 month age , eczema , immunodeficiency disease , use immunosuppressive medication . Subjects follow prior condition exclude : History immunodeficiency , chronic illness , autoimmune disease , use immunosuppressive medication . History anaphylaxis serious adverse reaction vaccine . Eczema within past year . History serious allergic reaction substance , require hospitalization emergent medical care ( e.g. , StevenJohnson syndrome , bronchospasm , hypotension ) . Prior psychiatric condition ( history suicide attempt past psychosis ) preclude compliance . History cancer unless surgical excision consider achieved cure . Prior Medication : Excluded : Prior HIV vaccine . Live attenuate vaccine within past 60 day . NOTE : Medically indicate subunit kill vaccine ( e.g. , influenza , pneumococcal ) exclude administer least 2 week prior HIV immunization . Experimental agent within past 30 day . Prior Treatment : Excluded : Receipt blood product immunoglobulins within past 6 month . It STRONGLY RECOMMENDED activity might expose subject HIV ( unprotected sex needle share ) avoid .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Vaccines , Synthetic</keyword>
	<keyword>Vaccinia Virus</keyword>
	<keyword>Viral Vaccines</keyword>
	<keyword>Smallpox Vaccine</keyword>
	<keyword>HIV-1</keyword>
	<keyword>AIDS Vaccines</keyword>
	<keyword>HIV Seronegativity</keyword>
	<keyword>HIV Preventive Vaccine</keyword>
</DOC>